Lucid Group Appoints Former Pfizer R&D Leader Rod MacKenzie, CMG, PhD, as Board Chair to Drive Next Phase of Global Growth and Innovation
March 18, 2026 |
Appointment marks a pivotal step in Lucid’s next phase of growth, strengthening its ability to translate complex science into real-world impact.
Lucid’s US Medical Affairs division unveils new proprietary insights tools to expand advisory capabilities.
LONDON & PHILADELPHIA, March 18, 2026 – Lucid Group, a global leader in healthcare communications and commercialisation, today announced that Rod MacKenzie, CMG, PhD, former Executive Vice President and Chief Development Officer at Pfizer, has been appointed as the new Chair of the Lucid Group Board of Directors. Dr MacKenzie will succeed Andy Black, who retired from the Board following the end of his term.
This appointment reflects a shared mission with Lucid Group to transform lives by ensuring innovative medicine doesn’t stop at approval but reaches the patients who need it most. His leadership marks a pivotal step in Lucid’s next phase of growth, strengthening its ability to translate complex science into real-world impact.
“Dr MacKenzie’s career is defined by his dedication to patient outcomes and a deep understanding that breakthrough science only matters when translated into action,” said Rick Sannem, CEO of Lucid Group. “His arrival supports our shared vision that we don’t just help clients talk about their science, we uncover the defining insights that shape behaviour so life-changing medicines find their rightful place in the market.”
Dr MacKenzie spent 34 years at Pfizer, where he led the Global Product Development division and oversaw 6,000 professionals dedicated to advancing innovative medicines and vaccines. He played a critical role in the development of both the Pfizer-BioNTech COVID-19 vaccine and antiviral, Paxlovid, in addition to serving on Pfizer’s Executive Leadership Team from 2016 to 2022. In recognition of his contributions to public health during the pandemic, he was appointed Companion of the Order of St Michael and St George by Queen Elizabeth II in 2022.
“Inventing and developing innovative medicines takes great science and execution. But translating that science into improved patient outcomes in clinical practice requires real strategic discipline,” said Dr MacKenzie. “Even brilliant science can struggle to break through, so innovative companies need a strategic partner like Lucid, whose integrated approach to solving complex challenges delivers changes in behaviours that successfully overcome treatment barriers. Lucid’s cre
ativity and unique data synthesis capabilities really stand out in the marketplace. I am thrilled to join the Lucid Board and share Lucid’s deep commitment to transforming lives across the globe.”
In addition to Dr MacKenzie’s appointment, Lucid’s US Medical Affairs division is unveiling new proprietary insights tools to expand its advisory capabilities at the Medical Affairs Professional Society (MAPS) conference in Denver from 22-25 March:
- Influence Amplifier™ – Closes the gap between communication and behaviour change by combining real-time behavioural insights, precision targeting, and adaptive analytics to expand peer-to-peer communication relevance and audience priorities.
- Impact Validator™ – Pinpoints precisely where efforts drive change through a five-step framework spanning clinical gaps and audience priorities, tailored interventions, omnichannel engagement, performance data, and adaptive refinement.
Together, these tools magnify and document scientific impact while delivering Precision Engagement™, a repeatable, self‑optimising cycle that continuously strengthens scientific influence, impact, and patient outcomes over time.
To demonstrate how Lucid Medical is enabling Medical Affairs teams to be strategic catalysts for change, it is offering free, 30-minute Impact Calibration™ sessions designed to map Medical Affairs teams’ current influence and spotlight opportunities for measurable growth.
About Lucid Group
Lucid Group, a global leader in healthcare communications and commercialisation, is driven by a mission to transform lives by bridging the gap between scientific discovery and patient impact. For life sciences organisations navigating their highest-stakes decisions, Lucid doesn’t just communicate science but ensures clients leave a lasting impact on the market and the patients they serve. Lucid brings together experts across Strategy Consulting, Scientific and Medical Communications, and Commercial Communications, fusing scientific rigour, strategic foresight, commercial ingenuity, creative storytelling, and deep human insight into an integrated force, powered by real-world evidence. This unique approach allows Lucid to uncover the ‘Lucid Truth’— the deep-seated insight that governs stakeholder behaviour and anchors bold, behaviour-changing ideas, executed at key moments and accelerated by AI and technology. To learn more about Lucid Group, visit www.wearelucidgroup.com and LinkedIn.
Media Contacts:
Chris Dougherty
CDougherty@reboundb2b.com
Elyse Cole
media@wearelucidgroup.com
This content was provided by Lucid Group Communications Limited
Company Details
Latest Content from Lucid Group Communications Limited
Attracting the best talent to build Lucid’s future
Q: Welcome to Lucid, Jon! Tell us what you love about recruitmentA: I love being able to play my part in shaping a company’s growth story through the hiring of...
A Lucid Group Thirsty Thursday Special: Beautiful Rejects
Last week, we waved goodbye to the post-holiday blues by welcoming back our legendary Thirsty Thursday sessions! Hosted by the Innovation Champions in Middlesex House, London, and broadcast to all...
Lucid Group’s winning talent team
The Lucid Group talent team has grown with two new Talent Acquisition Partners: Jon Turner and Ellen Field. To help you understand a bit more about them, their role, and the opportunities...
Solving healthcare problems: What needs to change?
In this month’s PME, Tanya Goodyear, Director of Innovation and Transformation at Lucid Group, details Lucid’s approach to solving healthcare problems and reflects on the learnings we can draw from...
Lucid Group celebrates a double win at Communiqué 2021
Lucid scooped a double win at this year’s Communiqué awards, the first face-to-face industry event since the start of the pandemic – making it an extra-special occasion for everyone attending....
Another Landmark Lucid Workiversary
We’re celebrating another landmark Workiversary with Richard Barry, Senior Medical Writer. Richard has now been a Lucidian for an impressive 10 years, so we thought it was only fitting to...
Summer Fridays are back at Lucid Group
Summer Fridays are back, bringing some much deserved R&R for our people.☀️A ‘Summer Friday’ means that employees are now actively encouraged to finish work from 2 pm on alternate Fridays...
The Spirit of Lucid Group
Since 2017, Lucid Group’s charity working group, LUCID SPIRIT, has been actively involved in helping to raise awareness and funds for its charity partners. At launch, Lucid Spirit partnered with the...
Staying in the loop – six principles for impactful integrated communications
In a digitalised world, accelerated by the COVID-19 pandemic, pharmaceutical companies must work smarter to engage busy external stakeholders with endless content at their fingertipsIn this month’s edition of PME James...
Lucid Group acquires US-based strategic brand consultants DiD
Lucid Group has acquired the US-based strategic brand consultants, DiD. This union will strengthen Lucid Group’s existing presence in the US and its ability to provide a compelling strategic, creative...